Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

66.7%

4 terminated/withdrawn out of 6 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 2

1(20.0%)

Phase 4

1(20.0%)

5Total

Phase 1(3)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05111600Phase 2Terminated

Open-label, Pivotal Clinical Trial to Confirm Efficacy and Safety of Autologous Grafts Containing Stem Cells Genetically Modified for Epidermis Restoration in Patients With Junctional Epidermolysis Bullosa

Role: lead

NCT05093166Phase 1Terminated

Clinical Trial to Assess the Safety and Efficacy of Investigational Product in Patients Due to Hypospadias Treatment Failure

Role: lead

NCT03288844Completed

Follow-up Study After ACLSCT for Restoration of Corneal Epithelium in Patients With LSCD Due to Ocular Burns

Role: lead

NCT02577861Phase 4Completed

Efficacy and Safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for Restoration of Corneal Epithelium in Patients With Limbal Stem Cell Deficiency

Role: lead

NCT03490331Phase 1Terminated

Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With JEB (HOLOGENE17)

Role: lead

NCT02984085Phase 1Terminated

Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB.

Role: lead

All 6 trials loaded